Nov 13-16, 2020, American Association for the Study of Liver Diseases (Digital Conference)

• Continued inequities in the hepatitis C cascade of care experiences by people who inject drugs in BC in 2019: a population-level linked data study
• The impact of direct acting antiviral treatments on all-cause, liver, and drug related mortality in a large population-based cohort study
• Women and the hepatitis C cascade of care in 2019: findings from the BC Hepatitis Testers Cohort

Aug 27-29, 2020, 55th Annual International Liver Congress organized by the European Association for the Study of the Liver (EASL) (Digital Conference)

• A latent class analysis to characterizing multivariable profiles of people living with Hepatitis C virus at a population level
• Population-level hepatitis C cascade of care among men who have sex with men in British Columbia, Canada
• Incidence of HCV infection among gbMSM in British Columbia, Canada: a population-based cohort study
• All-cause mortality and liver-related death following entecavir, tenofovir disoproxil fumarate or lamivudine therapy among treatment naive chronic hepatitis B patients in British Columbia, Canada
• Real-world effectiveness of sofosbuvir/velpatasvir/voxilaprevir as a hepatitis C virus infection salvage treatment
• Ethnic disparities in the risk of hepatitis C virus-related diabetes in a large population-based cohort in Canada
• Frequency of Prenatal Hepatitis C Screening and Diagnoses in British Columbia, 2008-2018

Jul 20-24, 2020, 33rd International Papillomavirus Conference (Digital Conference)

• The incidence of anal squamous cell carcinoma by HIV and MSM status in British Columbia, Canada (1990-2015)
• Incidence rates for oropharyngeal and oral cavity cancers among HIV-positive and HIV-negative individuals in British Columbia, Canada: a retrospective cohort study

Jul 6-10, 2020, 23rd International AIDS Conference (Digital Conference)

• Incidence rates of anal squamous cell carcinoma among HIV-positive and HIV-negative individuals by MSM status in British Columbia, Canada: a retrospective cohort study (1990-2015)
• The incidence of oropharyngeal and oral cavity cancers by HIV and MSM status in British Columbia, Canada (1990-2015)

Apr 30-May 3, 2020, 29th Annual Canadian Conference on HIV/AIDS Research (CAHR) (Digital Conference)

• Using population-level latent class analysis to classify people living with HCV in British Columbia (BC) for targeted program planning
• Incidence rates for oropharyngeal and oral cavity cancers among HIV-positive and HIV-negative individuals in British Columbia, Canada: a retrospective cohort study
• The incidence of anal squamous cell carcinoma by HIV and MSM status in British Columbia, Canada (1990-2015)
• Incidence of HCV infection among gbMSM in British Columbia, Canada: a population based cohort study

Mar 8-11, 2020, Conference on Retroviruses and Opportunistic Infections (Digital Conference)

• Syndemic of viral co-infections and incident end-stage renal disease

Mar 4-8, 2020, Asian Pacific Association for the Study of the Liver (Bali, Indonesia)

• Assessing the ethnic disparities in the HCV-related type 2 diabetes in an ethnically diverse large population-based cohort in British Columbia, Canada
• All-cause mortality and liver-related death following entecavir, tenofovir disoproxil fumarate or lamivudine therapy among treatment-naive chronic hepatitis B patients in British Columbia, Canada

Feb 28-Mar 1, 2020 Canadian Liver Meeting (Montreal, QC)

• The combined effect of sustained virologic response and opioid agonist therapy on cause-specific mortality among people living with chronic hepatitis C
• Increasing hepatitis C screening & new diagnoses in 10 British Columbia Provincial Correctional Centres from 2010-2019

Nov 25-27, 2019 Canadian Centre on Substance Use and Addiction's 2019 Issues of Substance Use Conference (Ottawa, ON)

• Chronic prescription opioid therapy associated with injection drug use: A large administrative cohort study

Nov 9-12, 2019 American Association for the Study of Liver Disease (Boston, MA)

• Hepatitis C virus reinfection after successful treatment with direct acting antiviral therapy in Canada

Nov 3-5, 2019 5th Canadian Cancer Research Conference (Ottawa, ON)

• Syndemics of HCV, HBV and HIV (co)infections on Colorectal and anal cancers: A population-based cohort study

Sep 11-13, 2019 8th International Conference on Hepatitis Care in Substance Users (Montreal, QC)

• Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in Canada
• Recent opioid agonist therapy and hepatitis C virus treatment uptake among people who inject drugs with chronic hepatitis C infection in a population based data linkage study

Jul 14-17, 2019 23rd International Society for Sexually Transmitted Diseases Research (Vancouver, BC)

• Hepatitis C incidence rate among people who inject drug (PWID) in British Columbia from 2000 to 2015

May 9-12, 2019 28th Annual Canadian Conference on HIV/AIDS Research (Saskatoon, SK)

• HCV, HBV and HIV syndemics are associated with higher mortality risk in a large population based cohort study
• Effectiveness of sofosbuvir / velpatasvir in treating hepatitis C virus infection in real- world setting
• Elevated HCV reinfection rates after cure or spontaneous clearance among HIV-infected and uninfected men who have sex with men

Mar 4-7, 2019 Conference on Retroviruses and Opportunistic Infections (Seattle, WA)

• Syndemic Viral Co-Infections and Incident Cerebrovascular and End-Stage Renal Disease (accepted but not presented)
• Survival After End-Stage Renal Disease Diagnosis in HCV-Infected Patients (accepted but not presented)

Nov 9-14, 2018 American Association for the Study of Liver Disease  (San Francisco, CA)

• Space- Time Clustering of HCV Reinfections to Inform Local Interventions for Prevention of Reinfection
• Effectiveness of Sofosbuvir/Velpatasvir in Treating Hepatitis C Virus Infections in Real-World Setting
• Loss to follow-up Among Hepatitis C Infected Patients Treated with Direct Acting Antiviral Agents
• Factors Associated with HBV, HCV and HIV Infection in British Columbia, Canada Differ by Ethnicity
• Linkage with Liver Care Among People Living with Hepatitis C Virus Infection in British Columbia
• Drug-related Deaths Among People Living with and without Hepatitis C in British Columbia (BC), Canada
• Hepatitis C Virus Reinfection after Successful Treatment with Direct-acting Antiviral Therapy in a Large Population-based Cohort
• Coinfections and Triple Infection with HCV, HBV and HIV Are Associated with Higher Mortality Risk in a Large Population Based Cohort Study
• Impact of HCV Sustained Virologic Response on Liver and Drug-related Mortality in a Large Population Based Cohort
• The Impact of HCV Sustained Virologic Response from Direct Acting Antiviral and Interferon-Based Treatments on Mortality in a Large Population Based Cohort Study
• Sustained Virologic Responses Reduces the Incidence of Extrahepatic Manifestations in Chronic Hepatitis C Infection
• Impact of Sequence of Diagnoses on All-Cause Mortality Among HBV/HCV Co-Infected Individuals: A Marker of Risk Stratification

Sep 12-14, 2018 International Population Data Linkage Network Conference (Banff, Alberta)

• Differential spatial distribution of hepatitis B virus by ethnicity in British Columbia, Canada: Expanded role of a large administrative cohort

Jun 14-17,2018 Global Hepatitis Summit (Toronto, ON)

• Hepatitis C Virus Reinfection after Successful Treatment with All-oral, Direct-Acting Antiviral Therapy in a large population-based cohort including people who inject drugs
• Prevention and care cascade for hepatitis C among people who inject drugs in British Columbia, Canada
• Syndemic Characterization of HCV< HBV< HIV Co-infection in a large population based cohort study
• Characteristics of people diagnosed with acute and chronic hepatitis B virus infection differ by ethnicity
• Lost to follow-up among Ledipasvir/sofosbuvir treated patients in Canada: The BC Hepatitis Testers Cohort

Apr 26-29, 2018 Canadian Conference on HIV/AIDS Research (Vancouver, BC)

• Prevention and care cascade for hepatitis C among people who inject drugs in British Columbia, Canada
• Identifying ‘core areas’ of HCV infection in British Columbia, Canada
• Population-level cascade of care for hepatitis C in British Columbia: Differences over time, by gender and birth cohort
• Population-level cascade of care for hepatitis C among people living with or without HIV infection
• Differing profiles of people who diagnose with acute and chronic Hepatitis B virus infection: A large population based study

Apr 11-15, 2018 53rd Annual International Liver Congress, organized by the European Association for the Study of the Liver (EASL) (Paris, France)

• Trends in decompensated cirrhosis and hepatocellular carcinoma in people with and without hepatitis C in British Columbia
• Hepatitis C virus reinfection after successful treatment with all-oral direct-acting antiviral therapy in British Columbia, Canada

Mar 20-24, 2018 International Workshop on HIV And Hepatitis Observational Databases (Fuengirola, Spain)

• Trends in decompensated cirrhosis and hepatocellular carcinoma in people with and without hepatitis C in British Columbia
• Prevention and care cascade for hepatitis C among people who inject drugs in British Columbia, Canada

Feb 7-11, 2018 Canadian Liver Meeting (Toronto, ON)

• Real-world effectiveness of sobosbuvir- based regimens for treatment among people who inject drugs and those in Opioid substitution therapy in Canada
• Real-world effectiveness of sobosbuvir-based regimens for treatment of Hepatitis C Genotypes 1-3: BC Hepatitis Testers Cohort (BCHTC)
• Spatial analysis of HCV infection in British Columbia
• Reduced risk of HCV seroconversion among individuals undergoing psychotherapy: A population based retrospective cohort of multi-testers 1992-2013
• What is killing people with HCV infection? Analysis of population based cohort in Canada
• Population –level cascade of care for hepatitis C in British Columbia: Differences over time, by gender and birth cohort.

Nov 23-24, 2017 CATIE Forum (Toronto, ON)

• What will it take: Eliminating Hepatitis 2030
• Ethnic Differences in Hepatitis in Hepatitis C Epidemiology and Care Cascade

Oct 20-24, 2017 AASLD Annual Liver Meeting (Washington, D.C.)

• Real-world Effectiveness of Sofosbuvir-based Regimens for Hepatitis C Treatment among People who Inject Drugs and those in Opoid substitution Therapy in Canada
• Real-world effectiveness of Sofosbuvir-based Regimens for Treatment of Hepatitis C Genotypes 1-3: BC Hepatitis Testers Cohort (BCHTC)
• Adherence to sofosbuvir and ledipasvir-sofosbuvir in British Columbia
• What is Killing People with HCV infection? Analysis of population based cohort in Canada

Sep 6-8, 2017 International Symposium on Hepatitis Care in Substance Users (INSHU) (New Jersey, USA)

• Hepatitis C Virus (HCV) Mortality attribution by Birth Cohort: British Columbia Hepatitis Testers Cohort (BCHTC)

May 14-17, 2017 Harm Reduction Conference (Montreal, QC)

• Hepatitis C treatment aces to direct-acting antivirals among people who inject drugs and are on opioid substitution therapy

Apr 19-23, 2017 International Liver Congress (Amsterdam, Netherlands)

• Are DAAs reducing barrier for HIV co-infected and people who inject drugs? A population based cohort study
• The impact of sustained virological response on long term risk of decompensated cirrhosis: The BC Hepatitis Testers Cohort

Apr 6-9, 2017 Canadian Association for HIV Research (Montreal, QC)

• The impact of sustained virological response on long term risk of decompensated cirrhosis: The BC Hepatitis Testers
• Shift in disparities in Hepatitis C treatment from interferon to DAA era: A population-based cohort study.
• Factors determining HIV risk among HCV infected individuals: The British Columbia Hepatitis Testers Cohort (BC-HTC)
• Impact of drug use and opioid substitution therapy on hepatitis C reinfection: The BC Hepatitis Testers Cohort
• Re-clearance of hepatitis C: Role of previous clearance and reinfection with a heterologous genotype
• Effect of OST and psychotherapy on HIV risk among HCV infected individuals
• Size Estimate of Key Populations who are at Risk of Acquiring HIV and HCV in British Columbia.
• Social disparities and co-evolution of HIV/HCV infections, mental disorders and substance use: the British Columbia Hepatitis Testers Cohort.
• Interdisciplinary Approach to Developing a Hepatitis C Testing Guide – Responding to the Needs of Local Physicians
• HIV diagnosis on first test and infection stage among HIV positive visible minority MSM in BC.
• A syndemic approach to assess the effect of substance Use and social disparities on the evolution of HIV/HCV infections in British Columbia
• Spatial and temporal trends of HIV and HCV diagnoses in British Columbia

Mar 3-6, 2017 6^th Canadian Association of Study of Liver’s Canadian Digestive Disease Week (CDDW) (Banff, AB)

• Shift in disparities in Hepatitis C treatment from interferon to DAA era: A population-based cohort study

Mar 3, 2017 6^th Canadian Symposium on Hepatitis C Virus (Banff, AB)

• Impact of treatment induced vs. spontaneous HCV clearance on the long term risk of hepatocellular carcinoma: BC Hepatitis Testers Cohort

Feb 13-16, 2017 Conference on Retroviruses and Opportunistic Infections (Seattle, WA)

• Effect of OST and psychotherapy on HIV risk among HCV infected individuals
• Risk profiles in mono infected TB patients and those co-infected with HCV and/or HIV

Nov 11-15, 2016 AASLD Annual Liver Meeting (Boston, MA)

• Role of primary T-cell immunodeficiency and Hepatitis B co-infection on spontaneous clearance of Hepatitis C: The BC Hepatitis Testers Cohort
• Impact of drug use and opioid substitution therapy on hepatitis C reinfection
• Long-term effect of sustained virological response on hepatocellular carcinoma risk in Canadians with hepatitis C virus infection
• Re-clearance of hepatitis C: Role of previous clearance and reinfection with a heterologous genotype
• Social disparities and co-evolution of HIV/HCV infections, mental disorders and substance use: the British Columbia Hepatitis Testers Cohort
• Impact of treatment induced vs spontaneous HCV clearance on the long term risk of hepatocellular carcinoma: BC Hepatitis Testers Cohort

May 12-15, 2016 Canadian Association for HIV Research (Winnipeg, MB)

• The British Columbia Hepatitis Testers Cohort
• Assessing Injection Drug Use from Diagnostic Codes in Administrative Healthcare Data: the British Columbia Hepatitis Testers Cohort
• Timing of Hepatitis B and C Diagnosis Relative to Hepatocellular Carcinoma Diagnosis in the BC Hepatitis Testers Cohort (BC-HTC)

Apr 13-17, 2016 International Liver Congress (Barcelona, Spain)

• The BC Hepatitis Testers Cohort: The Population Level Hepatitis C Cascade of Care in British Columbia, Canada
• Does alcohol dependency explain differences in rates of decompensated cirrhosis among people with a hepatitis C notification? An international comparison

Mar 30-Apr 2, 2016 AMMI Canada - CACMID Annual Conference (Vancouver, BC)

• Hepatitis C Virus (HCV) Mortality Patterns in the British Columbia Hepatitis Testers Cohort (BC-HTC)

Feb 26, 2016 5^th Canadian Symposium on HCV (Montréal, QC)

• The BC Hepatitis Testers Cohort (BC-HTC): the population-level hepatitis C Cascade of Care, BC, Canada, 1992-2012

Nov, 17 2015 AASLD Annual Liver Meeting (San Francisco, CA)

• Hepatitis C Virus (HCV) Mortality Patterns in the British Columbia Hepatitis Testers Cohort (BC-HTC)
• Timing of Hepatitis B and C Diagnosis Relative to Hepatocellular Carcinoma Diagnosis in the BC Hepatitis Testers Cohort (BC-HTC)

May, 29 2015 Hepatology Update (Toronto, ON)

• The Epidemiology of HCV in Canada

Apr, 28 2014 International Health Data Linkage Conference (Vancouver, BC)

• British Columbia Hep C-HIV Testers Cohort: A Linkage to Monitor Hepatitis C-Related Outcomes

Feb 28-Mar 1, 2020 Canadian Liver Meeting (Montreal, QC)

• A population-level latent class analysis of people living with hepatitis C virus for effective program planning and health care resource distribution (Poster)
• Treatment differential in HCV treatment prescribers in British Columbia over time (Poster)
• Ethnic disparities in the risk of hepatitis C virus-related diabetes in a large population-based cohort in Canada (Poster)
• Syndemic of viral co-infections and incident end-stage renal disease (Poster)
• Trends in hepatocellular carcinoma survival among individuals infected with HBV and/or HCV in British Columbia, Canada (2001-2016) (Poster)
• Association between prescription opioids and Hepatitis C virus seroconversion among people who use injection drugs in British Columbia (Poster)
• Current Opioid Agonist Therapy is associated with hepatitis C virus treatment uptake among People Who Inject Drugs in a population based data linkage study(Poster)
• Hepatitis C virus reinfection after successful treatment with direct acting antiviral therapy in Canada (Poster)
• Real-world effectiveness of sofosbuvir/velpatasvir/voxilaprevir as a hepatitis C virus infection salvage treatment (Poster)
• Geographic distribution of people living with hepatitis C in British Columbia: an application of latent class analysis and disease mapping (Poster)
• Frequency of Prenatal Hepatitis C Screening and Diagnoses in British Columbia, 2008-2018 (Poster)

Nov 9-12, 2019 American Association for the Study of Liver Disease (Boston, MA)

• • Characterization and identification of gaps within the HCV cascade of care among ethnic groups: a population-based cohort study (Poster)
  • Effectiveness of sofosbuvir / velpatasvir in treating hepatitis C virus infection in a real- world setting (Poster)
  • Real-world effectiveness of sofosbuvir /velpatasvir/voxilaprevir as a hepatitis C virus infection salvage treatment (Poster)
  • Liver-related death among chronic hepatitis B patients initiating tenofovir, entecavir or lamivudine treatment in British Columbia (Poster)
  • Hepatitis C Virus Reinfection after Successful Treatment with Direct-Acting Antiviral Therapy among MSM (Poster)

</
Sep 11-13, 2019 8th International Conference on Hepatitis Care in Substance Users (Montreal, QC)

• • • Association between prescription opioids and Hepatitis C virus seroconversion among people who use injection drugs in British Columbia (Poster)
    • Geographic cascade of HCV care: A tool for targeted interventions and program evaluation (Poster)

Aug 5-6, 2019 Australasian Viral Hepatitis Elimination Conference (Sydney, Australia)

• • • Hepatitis C virus treatment uptake differs according to recency of opioid agonist therapy among people who inject drugs with chronic hepatitis C infection (Poster)

Jul 14-17, 2019 23rd International Society for Sexually Transmitted Diseases Research (Vancouver, BC)

• • • MSM predictive modeling within a large, linked database of laboratory, surveillance, and administrative healthcare records (Poster)
    • Evolution of Hepatitis C cascades of care among HIV and hepatitis B co-infected patients in British Columbia, Canada (Poster)
    • Elevated HCV reinfection rates after cure or spontaneous clearance among HIV-infected and uninfected men who have sex with men (Poster)
    • Cancer Risk Among People with HIV, HBV and/or HCV Infections (Poster)

May 24-26, 2019 Canadian Liver Meeting (Montreal, QC)

• • • Elevated HCV reinfection rates after cure or spontaneous clearance among HIV-infected and uninfected men who have sex with men (Poster)
    • Spatio-temporal detection of HCV reinfection clusters: an approach to inform interventions for prevention of reinfection (Poster)
    • Characterization and identification of gaps within the HCV cascade of care among ethnic minority groups: a population-based cohort study (Poster)
    • Hepatitis C cascade of care and factors associated with treatment uptake among people who inject drugs in British Columbia in 2017 (Poster)
    • Hepatitis C incidence rate among people who inject drug (PWID) in British Columbia from 2000 to 2015 (Poster)

May 9-12, 2019 28th Annual Canadian Conference on HIV/AIDS Research (Saskatoon, SK)

• • • The impact of HCV SVR from direct acting antiviral and interferon-based treatments on mortality in a large population based cohort study (Poster)
    • Drug-related deaths among hepatitis C positive and negative people in British Columbia, Canada (Poster)

Apr 10-14, 2019 54th Annual International Liver Congress, organized by the European Association for the Study of the Liver (Vienna, Austria)

• • • Factors associated with hepatitis C treatment uptake among people who inject drugs in a population-based data linkage study (Poster)
    • The impact of HCV SVR from direct acting antiviral and interferon-based treatments on HCC in a large population based cohort study (Poster)
    • Cancer Risk Among People with HIV, HBV and/or HCV Infections (Poster)
    • Elevated HCV reinfection rates after cure or spontaneous clearance among HIV-infected and uninfected men who have sex with men (Poster)

Mar 4-7, 2019 Conference on Retroviruses and Opportunistic Infections (Seattle, WA)

• • • Hepatitis C cascade of care among people who inject  drugs in British Columbia  in 2017 (Poster)

Feb 26-28, 2019 BC Quality Forum

• • • Integrating health and administrative datasets to improve quality of care: The BC-HTC (Poster)

Apr 27-29 2018 Canadian Association for HIV Research (Vancouver, BC)

• • • Differing profiles of people diagnosed with acute and chronic hepatitis B virus infection: a large population based study
    • Population-level cascade of care for Hepatitis C in British Columbia: Differences over time, by gender and birth cohort

Mar 22-2 2018 International Workshop on HIV and Hepatitis Observational Databases (Fuengirola, Spain)

• • • Trends in decompensated cirrhosis and hepatocellular carcinoma in people with and without hepatitis C in British Columbia
    • Prevention and care cascade for hepatitis C among people who inject drugs in British Columbia, Canada

Feb 9-11 2018 Canadian Liver Meeting (Toronto, On)

• • • Real-world Effectiveness of Sofosbuvir-based regimens for Treatment of Hepatitis C Genotypes 1-3: BC Hepatitis Testers Cohort (BC-HTC)
    • Spatial analysis of HCV infection in British Columbia, Canada
    • What is Killing People with HCV Infection? Analysis of a population-based cohort in Canada
    • Psychotherapy reduces the risk of HCV Sero-conversion among multi-testers from BC Hepatitis testers cohort

Oct 20-24 2017  AASLD Annual Liver Meeting  (Washington, D.C)

• • • Real-world Effectiveness of Sofosbuvir-based regimens for Hepatitis C Treatment among People who inject Drugs and those in Opioid substitution Therapy in Canada
    • Real-world Effectiveness of Sofosbuvir-based Regimens for treatment of Hepatitis C Genotypes 1-3: BC Hepatitis Testers Cohort (BCHTC)
    • Adherence to sofosbuvir and ledipasvir-sofosbuvir in British Columbia
    • What is Killing People with HCV infection? Analysis of population based cohort in Canada

Sept 6-8, 2017 International Symposium on Hepatitis Care in Substance Users (INSHU) (New Jersery, USA)

• • • Hepatitis C Virus (HCV) Mortality attribution by birth cohort: British Columbia Hepatitis Testers Cohort (BCHTC)

May 14-17, 2017 Harm Reduction Conference (Montreal,QU)

• • • Hepatitis C treatment access to direct-acting antivirals among people who inject drugs and are on opioid substitution therapy

Apr 6-9^th 2017 Canadian Association for HIV Research (Montreal,QU)

• • • Hepatitis C re-clearance and lack of cross-genotype immunity in a large population cohort
    • Spatial and temporal trends of HIV and HCV diagnoses in British Columbia

Feb 13-16, 2017 Conference on Retrovirus and Opportunistic Infections (Seattle, WA)

• • • Effects of OST and psychotherapy on HIV risk among HCV infected individuals
    • Risk profiles in mono infected TB patients and those co-infected with HCV and/or HIV

Dec 6-8th, 2016 Canadian Immunization Conference (Ottawa)

• • • Variable effects of Repeat Vaccination against Influenza b Illness by Season 2010-11 to 2014-15

Nov 11-15,2016 AASLD Annual Liver Meeting  (Boston, MA)

• • • Role of primary T-cell immunodeficiency and Hepatitis B co-infection on spontaneous clearance of Hepatitis C: The BC Hepatitis Testers Cohort
    • Re-clearance of hepatitis C: Role of  previous clearance and reinfection with a heterologous genotype
    • Social disparities and co-evolution of HIV/HCV infections,mental disorders and substance use: the British Columbia Hepatitis Testers Cohort
    • Impact of treatment induced vs spontaneous HCV clearance on the long term risk of hepatocellular carcinoma; BC Hepatitis Testers Cohort  View Poster

May 12-15, 2016 – Canadian Association for HIV Research (Winnipeg, MB)

• • • Assessing Injection Drug Use from Diagnostic Codes in Administrative Healthcare Data: the British Columbia Hepatitis Testers Cohort

Feb, 26 2016 5^th Canadian Symposium on HCV (Montréal, QC)

• • • The BC Hepatitis Testers Cohort (BC-HTC): the population-level hepatitis C Cascade of Care, BC, Canada, 1992-2012

Mar 2, 2015 Canadian Association for the Study of the Liver (Banff, AB)

• • • Hepatitis C Epidemiology in British Columbia to Inform Screening and Treatment Response